title: Medulloblastoma: clinicopathologic evaluation of 42 pediatric cases.
abstract: OBJECTIVE
  The aim of this study was to assess the prognostic value of MIB-1 and p53 in the pediatric medulloblastoma group.
  
  
  METHODS
  Forty-two pediatric medulloblastoma cases diagnosed in a single institution during the past 10 years were evaluated. Follow-up data were available for 35 patients.
  
  
  RESULTS
  The immunoreactivity of MIB-1 ranged from 10% to 95%; p53 immunoreactivity was found in five cases. Of the 35 patients with follow-up, 34 patients received a combination of chemotherapy and radiotherapy, while one received chemotherapy alone. The follow-up period ranged from 5 to 64 months. Of the 35 patients, 21 were alive without any evidence of recurrent disease, three were alive with evidence of recurrent disease and 11 died of disease during follow-up. The mean survival for these 11 patients was 21.9+/-10.4 months. Of the 35 cases, 16 had MIB-1 value of 25% or lower and 19 had a value of 26% or more. Of the 16 cases with low MIB-1 value, six died of disease; of the 19 cases with high MIB-1 value, five died of disease. The statistical difference between MIB-1 and prognosis was not significant. Three of the 35 (8.5%) cases were found to be positive with p53 protein; no correlation was observed between p53 immunoreactivity and prognosis.
  
  
  CONCLUSIONS
  It appears that the MIB-1 value and p53 immunoreactivity have no relation with prognosis in pediatric medulloblastomas. However, it is convenient to support these findings with large series.
authors.affiliation: Department of Pathology, Ege University Faculty of Medicine, Izmir, Turkey. yesim.ertan@ege.edu.tr
authors.forename: Yeşim
authors.initials: Y
authors.lastname: Ertan
authors.forename: Murat
authors.initials: M
authors.lastname: Sezak
authors.forename: Bengü
authors.initials: B
authors.lastname: Demirağ
authors.forename: Mehmet
authors.initials: M
authors.lastname: Kantar
authors.forename: Nazan
authors.initials: N
authors.lastname: Cetingül
authors.forename: Tuncer
authors.initials: T
authors.lastname: Turhan
authors.forename: Yusuf
authors.initials: Y
authors.lastname: Erşahin
authors.forename: Saffet
authors.initials: S
authors.lastname: Mutluer
authors.forename: Yavuz
authors.initials: Y
authors.lastname: Anacak
authors.forename: Taner
authors.initials: T
authors.lastname: Akalin
mesh_terms: D014408:Biomarkers, Tumor / Q000378:metabolism*; D001932:Brain Neoplasms / Q000378:metabolism* / Q000473:pathology* / Q000628:therapy; D017024:Chemotherapy, Adjuvant; D002648:Child; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D007150:Immunohistochemistry; D019394:Ki-67 Antigen / Q000378:metabolism; D008297:Male; D008527:Medulloblastoma / Q000378:metabolism* / Q000473:pathology* / Q000628:therapy; D011237:Predictive Value of Tests; D011379:Prognosis; D018714:Radiotherapy, Adjuvant; D016159:Tumor Suppressor Protein p53 / Q000378:metabolism*; D044767:Ubiquitin-Protein Ligases / Q000378:metabolism*
chemical_list: D014408:Biomarkers, Tumor; D019394:Ki-67 Antigen; D016159:Tumor Suppressor Protein p53; C513496:MIB1 ligase, human; D044767:Ubiquitin-Protein Ligases